TRICC-C: A Multicenter, Randomized, Phase II Trial: BIBF 1120 vs. Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC).
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Nintedanib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms TRICC-C
- 01 Jun 2012 Planned End Date changed from 1 Dec 2013 to 1 Jun 2013, based on an abstract presented at ASCO 2012.
- 01 Jun 2012 Planned number of patients changed from 2 to 180, as reported at ASCO 2012.
- 05 Apr 2012 Planned number of patients added 2 as reported by ClinicalTrials.gov.